Global research trends and hotspots in blood-based biomarkers for Alzheimer's disease: a bibliometric analysis.

IF 5.2 2区医学 Q2 GERIATRICS & GERONTOLOGY

Frontiers in Aging Neuroscience Pub Date : 2026-09-29 eCollection Date: 2026-01-01 DOI:10.3389/fnagi.2026.1886781

Shengjie Wang, Junyao Zhang, Shaojun Sun, Renlong Xiao, Zhiyi Zhang, Junyan Yao

{"title":"Global research trends and hotspots in blood-based biomarkers for Alzheimer's disease: a bibliometric analysis.","authors":"Shengjie Wang, Junyao Zhang, Shaojun Sun, Renlong Xiao, Zhiyi Zhang, Junyan Yao","doi":"10.3389/fnagi.2026.1886781","DOIUrl":null,"url":null,"abstract":"Background: Blood-based biomarkers (BBMs) are rapidly reshaping the diagnostic and translational landscape of Alzheimer's disease (AD), offering a scalable alternative to cerebrospinal fluid (CSF) assays and positron emission tomography (PET). This paper aims to conduct bibliometric analysis on the hotspots and trends in this field.Methods: Publications addressing AD-related blood/plasma/serum biomarkers from 1 January 2011 to 29 November 2025 were retrieved from the Web of Science Core Collection (WoSCC) and Scopus. Only English-language articles and reviews were included. VOSviewer, CiteSpace, and the R package bibliometrix were used to evaluate publication trends, collaboration networks (countries, institutions, authors), co-cited journals and references, and keyword evolution.Results: A total of 1,771 publications with 53,568 citations were included. Annual output rose steadily and accelerated after 2018, while 2025 records covered approximately the first 11 months of the year. The USA (795 publications) and China (478) were the most productive countries, whereas the UK and Sweden showed strong citation impact and collaboration intensity. The University of Gothenburg (263) and Sahlgrenska University Hospital (237) were the leading institutions. Henrik Zetterberg (218) and Kaj Blennow (185) were the most prolific authors. Co-citation analysis identified the NIA-AA biological research framework and validation studies of plasma amyloid-beta (Aβ) and plasma phosphorylated tau (p-tau) as the intellectual base. Keyword and burst analyses indicated a clear shift from early themes (e.g., proteomics and oxidative stress) toward clinically oriented topics, including plasma p-tau217/p-tau181, diagnostic performance, and implementation recommendations.Conclusion: Research on AD BBMs has entered a phase of rapid growth and clinical translation. Plasma phosphorylated tau (especially p-tau217) is the leading biomarker for detecting AD-specific pathology. Plasma Aβ ratios play a supportive role in amyloid triage, while neurodegeneration (NfL) and astroglial (GFAP) markers provide complementary information for prognosis and monitoring. Future priorities include real-world implementation, assay standardization, and integration of multi-marker panels into biological diagnostic/staging frameworks.","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"18 ","pages":"1886781"},"PeriodicalIF":5.2000,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13659226/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Aging Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fnagi.2026.1886781","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Blood-based biomarkers (BBMs) are rapidly reshaping the diagnostic and translational landscape of Alzheimer's disease (AD), offering a scalable alternative to cerebrospinal fluid (CSF) assays and positron emission tomography (PET). This paper aims to conduct bibliometric analysis on the hotspots and trends in this field.

Methods: Publications addressing AD-related blood/plasma/serum biomarkers from 1 January 2011 to 29 November 2025 were retrieved from the Web of Science Core Collection (WoSCC) and Scopus. Only English-language articles and reviews were included. VOSviewer, CiteSpace, and the R package bibliometrix were used to evaluate publication trends, collaboration networks (countries, institutions, authors), co-cited journals and references, and keyword evolution.

Results: A total of 1,771 publications with 53,568 citations were included. Annual output rose steadily and accelerated after 2018, while 2025 records covered approximately the first 11 months of the year. The USA (795 publications) and China (478) were the most productive countries, whereas the UK and Sweden showed strong citation impact and collaboration intensity. The University of Gothenburg (263) and Sahlgrenska University Hospital (237) were the leading institutions. Henrik Zetterberg (218) and Kaj Blennow (185) were the most prolific authors. Co-citation analysis identified the NIA-AA biological research framework and validation studies of plasma amyloid-beta (Aβ) and plasma phosphorylated tau (p-tau) as the intellectual base. Keyword and burst analyses indicated a clear shift from early themes (e.g., proteomics and oxidative stress) toward clinically oriented topics, including plasma p-tau217/p-tau181, diagnostic performance, and implementation recommendations.

Conclusion: Research on AD BBMs has entered a phase of rapid growth and clinical translation. Plasma phosphorylated tau (especially p-tau217) is the leading biomarker for detecting AD-specific pathology. Plasma Aβ ratios play a supportive role in amyloid triage, while neurodegeneration (NfL) and astroglial (GFAP) markers provide complementary information for prognosis and monitoring. Future priorities include real-world implementation, assay standardization, and integration of multi-marker panels into biological diagnostic/staging frameworks.

查看原文本刊更多论文

阿尔茨海默病血液生物标志物的全球研究趋势和热点：文献计量学分析。

背景：基于血液的生物标志物（BBMs）正在迅速重塑阿尔茨海默病（AD）的诊断和转化格局，为脑脊液（CSF）检测和正电子发射断层扫描（PET）提供了可扩展的替代方案。本文旨在对该领域的热点和趋势进行文献计量学分析。方法：从Web of Science Core Collection （WoSCC）和Scopus检索2011年1月1日至2025年11月29日与ad相关的血液/血浆/血清生物标志物的出版物。仅包括英文文章和评论。使用VOSviewer、CiteSpace和R软件包bibliometrix来评估出版趋势、合作网络（国家、机构、作者）、共同被引期刊和参考文献以及关键词演变。结果：共纳入文献1771篇，被引53568次。2018年之后，年产量稳步增长并加速，而2025年的记录涵盖了今年前11个 月。美国（795篇）和中国（478篇）是产出最高的国家，而英国和瑞典则表现出较强的引文影响和合作强度。哥德堡大学（263）和萨尔格伦斯卡大学医院（237）是主要机构。Henrik Zetterberg（218）和Kaj Blennow（185）是最多产的作家。共引分析确定了NIA-AA生物学研究框架和血浆淀粉样蛋白- β (Aβ)和血浆磷酸化tau （p-tau）的验证研究作为知识基础。关键词和突发分析表明，从早期的主题（如蛋白质组学和氧化应激）向临床导向的主题（包括血浆p-tau217/p-tau181、诊断性能和实施建议）明显转变。结论：AD脑卒中的研究已进入快速发展和临床转化阶段。血浆磷酸化tau蛋白（尤其是p-tau217）是检测ad特异性病理的主要生物标志物。血浆a β比值在淀粉样蛋白分类中发挥支持作用，而神经变性（NfL）和星形胶质细胞（GFAP）标志物为预后和监测提供补充信息。未来的优先事项包括现实世界的实施，测定标准化，以及将多标记面板整合到生物诊断/分期框架中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Aging Neuroscience GERIATRICS & GERONTOLOGY-NEUROSCIENCES

CiteScore

6.30

自引率

8.30%

发文量

1426

期刊介绍： Frontiers in Aging Neuroscience is a leading journal in its field, publishing rigorously peer-reviewed research that advances our understanding of the mechanisms of Central Nervous System aging and age-related neural diseases. Specialty Chief Editor Thomas Wisniewski at the New York University School of Medicine is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.